Institutional investors purchased a net $2.7 million shares of ANTH during the quarter ended March 2015. This may signal that the smart money is gaining interest in this company as the 35.02% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
APO ASSET MANAGEMENT GMBH Bought 9.2 Thousand shares of Anthera Pharmaceuticals I...